Mechanism of Action of Daridorexant
Daridorexant works by blocking both orexin receptors (OX1R and OX2R), thereby preventing wake-promoting neuropeptides orexin A and orexin B from maintaining wakefulness, which suppresses the brain's wake drive and promotes sleep. 1
Detailed Pharmacological Mechanism
Daridorexant is a dual orexin receptor antagonist (DORA) that specifically binds to and inhibits both orexin receptor subtypes with high affinity (Ki = 0.47 nM for OX1R and 0.93 nM for OX2R) 1.
How It Differs from Traditional Sleep Medications
Unlike traditional insomnia medications that work as positive allosteric modulators of GABA-A receptors (such as benzodiazepines and Z-drugs), daridorexant targets a completely different neurobiological pathway 2. The orexin neuropeptide signaling system is a key regulator of wakefulness in the brain. By blocking the binding sites where wake-promoting orexins would normally act, daridorexant specifically reduces wake drive rather than broadly enhancing inhibitory neurotransmission throughout the brain 1, 2.
Clinical Implications of This Mechanism
This targeted mechanism offers several advantages:
- Promotes natural, surmountable sleep - The sleep induced is more physiological rather than sedative in nature 2
- Preserves cognitive function - Unlike GABA-ergic agents, memory and cognition remain intact 2
- No physical dependence - Clinical trials showed no withdrawal symptoms upon discontinuation, suggesting daridorexant does not produce physical dependence 1
- Maintains daytime functioning - By specifically targeting wake drive rather than causing generalized CNS depression, next-day residual effects are minimized 3, 4
Additional Pharmacological Properties
The drug demonstrates dose-proportional exposure from 25-50 mg, reaches peak plasma concentrations in 1-2 hours, has a terminal half-life of approximately 8 hours, and is primarily metabolized by CYP3A4 1. This pharmacokinetic profile was specifically designed to cover the entire night while avoiding morning residual activity 2.
Important caveat: While daridorexant may also have anxiolytic-like effects through orexin system modulation of stress response centers 5, its FDA-approved indication is specifically for insomnia treatment through wake drive suppression 1.